Oziltus in Sri Lanka

Oziltus - overview

Oziltus (denosumab-mobz) is manufactured by Celltrion and indicated for Prevention of skeletal-related events in MM / bone mets; giant cell tumor of bone; hypercalcemia of malignancy. It is a approved by the US FDA in 2026 and may be accessible to patients in Sri Lanka through a Named Patient Program or personal-import pathway.

Access in Sri Lanka

Sri Lanka's NMRA permits named-patient import for rare-disease specialty drugs via physician request.

How Reserve Meds coordinates access in Sri Lanka

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Sri Lanka-specific eligibility.
3. Treating physician in Sri Lanka issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Oziltus from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Sri Lanka.

Typical timeline for Sri Lanka

End-to-end, most requests are completed in 2-6 weeks. Sri Lanka's tier 3 regulatory maturity typically supports longer processing times.

What patients and physicians in Sri Lanka ask

• Is the pathway legal in Sri Lanka? Yes - it operates under Sri Lanka's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Sri Lanka able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Oziltus in Sri Lanka

Request Oziltus